Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.

In this part of his Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, explores the contributing ...

Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...

Legos holds a PhD in physiology from Temple University and an MBA in finance from Villanova University. He has also written ...

Biljana Naumovic discusses the importance of finding ways to reach out to underserved communites.

Dan Rizzo, global head of Veeva Business Consulting, spoke with Pharmaceutical Executive about the state of product launches ...

In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI discusses ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

In a statement sent to Pharmaceutical Executive, AMCP CEO Susan A. Cantrell, MHL, RPh, CAE, said, “Although President Trump’s ...

In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI identifies ...